Sernova gets under the skin

Thanks to the deal it signed last month with Evotec, Sernova will soon have a ready supply of off-the-shelf islet cells to add to its implanted Cell Pouch device. The combination is not yet in formal preclinical trials, but the group believes it can replace its current flagship project, which uses donor-derived islet cells, and go on to be nothing less than a functional cure for type 1 diabetes.